| Drug Name: | RB90740(fused pyrazine mono-N-oxide bioreductive drugs) (108307-65-9) |
|---|---|
| PubChem ID: | 150563 |
| SMILES: | CN1CCN(CC1)C2=NC3=C(C=C2)[N+](=C(C4=NCCN34)C5=CC=CC=C5)[O-] |
| InchiKey: | CKRPRSXFNWNTOW-UHFFFAOYSA-N |
| Therapeutic Category: |
| Molecular Weight (dalton) | : | 362.437 |
| LogP | : | 1.6966 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 6 |
| Hydrogen Bond Donor Count | : | 0 |
| Total Polar Surface Area | : | 61.04 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Hypoxia | Cytochrome P450 reductase (P16435) | Relationship between the intracellular levels of P450 reductase and cytochrome b5 reductase and the hypoxic toxicity of RB90740 [ ADR Type 1 ] | Enzymology of the reduction of the novel fused pyrazine mono-n-oxide bioreductive drug, RB90740 roles for P450 reductase and cytochrome b5 reductase |
| Hypoxic Toxicity | NADH-cytochrome b5 reductase (P00387) | Relationship between the intracellular levels of P450 reductase and cytochrome b5 reductase and the hypoxic toxicity of RB90740. [ ADR Type 1 ] | Enzymology of the reduction of the novel fused pyrazine mono-n-oxide bioreductive drug, RB90740 roles for P450 reductase and cytochrome b5 reductase |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category
| Toxicity | Source |
|---|